Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 5/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.34 |
| ▸ | ATR | Q13535 | 4/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 4/20 | 0.33 |
| ▸ | CHUK | O15111 | 2/20 | 0.32 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4267662 | 0.76 | IKBKB (0.40) | IKBKBATRPIM1SCD | |
| SCHEMBL4100789 | 0.73 | SCD (0.60) | IKBKBSCD | |
| SCHEMBL22051458 | 0.69 | IKBKB (0.50) | IKBKBMKNK1MKNK2CHUK | |
| SCHEMBL20472448 | 0.67 | IKBKB (0.48) | IKBKBMKNK1MKNK2PIM1CHUK | |
| SCHEMBL4743748 | 0.65 | SCD (0.48) | IKBKBSCDCHUK | |
| SCHEMBL30465743 | 0.64 | MKNK1 (0.53) | IKBKBMKNK1MKNK2PIM1CHUK | |
| SCHEMBL4094392 | 0.63 | SCD (0.60) | IKBKBSCD | |
| SCHEMBL6012158 | 0.61 | MKNK1 (0.48) | IKBKBMKNK1MKNK2PIM1SCD | |
| SCHEMBL4087727 | 0.60 | SCD (0.41) | IKBKBSCDCHUK | |
| SCHEMBL29159564 | 0.60 | CDK8 (0.47) | PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099200-A1 | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099200-A1 | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | SCD, SCD5, SREBF1 | IKBKB 714/4885MKNK1 2117/4885MKNK2 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.